echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Express to Eradicate Helicobacter pylori Infection, FDA Approves Innovative Combination Therapy

    Express to Eradicate Helicobacter pylori Infection, FDA Approves Innovative Combination Therapy

    • Last Update: 2022-05-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ▎WuXi AppTec Content Team Editor Today, Phathom Pharmaceuticals announced that the U.
    S.
    FDA has approved Voquezna Triple Pak (Vonolaxa, Amoxicillin, Clarithromycin triple combination) and Voquezna Dual Pak (Vonolaxa, Amoxicillin dual combination) combination) for the treatment of Helicobacter pylori infection in adults
    .

    The press release states that both combinations contain vornoxan, a "first-in-class" potassium-competitive acid blocker that is the first derived from a new drug class approved in the U.
    S.
    in more than 30 years.
    Innovative acid suppression therapy
    .

    About 50% of the world's population is infected with Helicobacter pylori
    .

    Chronic inflammation triggered by H.
    pylori infection can lead to a range of diseases in infected individuals, including dyspepsia, peptic ulcer disease, gastric cancer, and mucosa-associated lymphoid tissue (MALT) lymphoma
    .

    Acid suppression therapy has been one of the mainstays of the treatment regimen for H.
    pylori infection, which enhances the effect of antibiotics
    .

    More potent acid-suppressing drugs, such as vonolaxan, may improve eradication rates with current treatment regimens
    .

    Vonolaxen is a novel potassium ion-competitive acid blocker (P-CAB), which can competitively block the binding of potassium ions to hydrogen/potassium ATPase, thereby rapidly inhibiting gastric acid secretion
    .

    Due to its long half-life and longer duration of action, vonoprazine is regarded as a potent long-acting proton pump inhibitor (PPI)
    .

    The FDA has previously granted Qualified Infectious Disease Product Designation (QIDP) and Fast Track designation to vonoprazan triple and dual combination therapy for the treatment of H.
    pylori infection
    .

    ▲Vonolaxine has a unique mechanism of action (Image source: Phathom Pharmaceuticals official website) FDA approval is based on the results of a pivotal Phase 3 clinical trial involving 1046 patients
    .

    The trial results showed that the triple and dual combination therapy of vonolaxine met the primary endpoint of the trial, with a non-inferiority criterion for eradication compared with the triple combination therapy based on lansoprazole
    .

    In the modified intention-to-treat population (mITT), eradication rates were 84.
    7% for the vonorasen triple combination, 78.
    5% for the dual combination, and 78.
    8% for the lansoprazole triple combination
    .

    ▲The combination therapy of vonoprazol reached the primary endpoint of the Phase 3 clinical trial (Image source: Phathom Pharmaceuticals official website) In the entire patient population including clarithromycin-resistant Helicobacter pylori infection, the eradication rate of the triple combination of vonoprazol It was 80.
    8%, and the double combination therapy was 77.
    2%, both of which were better than the lansoprazole triple combination therapy (68.
    5%)
    .

    "The approval of the Voquezna regimen gives physicians and patients two treatment options
    .

    They have demonstrated superior eradication in the entire patient population compared to the proton pump inhibitor lansoprazole-based combination therapy in pivotal clinical trials.
    "Helicobacter pylori eradication rates are declining due to antibiotic resistance, inadequate levels of acid suppression, and complex treatment regimens," said Terrie Curran, Phathom's President and CEO
    .
    " Patients need new treatments that address the limitations of existing treatments .
    , we look forward to bringing Vonolaxan-based treatment options to millions of people with H.
    pylori infection .





    "Reference: [1] Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H.
    pylori Infection in Adults.
    Retrieved May 3 , 2022, from https:// amoxicillin-clarithromycin-and-VOQUEZNA-DUAL-PAK-vonoprazan-amoxicillin-for-the-Treatment-of-H-pylo.
    htmlDisclaimer: WuXi AppTec content team focuses on global biomedical health research progress
    .

    This article is for information only For the purpose of communication, the opinions in this article do not represent WuXi AppTec's position, nor do they support or oppose the opinions expressed in the article
    .

    This article is not a treatment plan recommendation
    .

    If you need treatment plan guidance, please go to a regular hospital for treatment
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.